Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, one cohort, non-randomized, phase I/II study. The aim
is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy
(HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect
will be compared with historical radiation therapy-alone control data.